Citigroup’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13,848
| Closed | -$297K | – | 5838 |
|
|
2026
Q1 | $297K | Sell |
13,848
-10,246
| -43% | -$144K | ﹤0.01% | 3806 |
|
|
2025
Q4 | $225K | Buy |
24,094
+16,121
| +202% | +$135K | ﹤0.01% | 3945 |
|
|
2025
Q3 | $56.2K | Sell |
7,973
-100,398
| -93% | -$691K | ﹤0.01% | 4453 |
|
|
2025
Q2 | $704K | Sell |
108,371
-56,305
| -34% | -$387K | ﹤0.01% | 3405 |
|
|
2025
Q1 | $1.31M | Buy |
164,676
+8,442
| +5% | +$90.9K | ﹤0.01% | 3054 |
|
|
2024
Q4 | $1.98M | Buy |
156,234
+108,164
| +225% | +$1.51M | ﹤0.01% | 2831 |
|
|
2024
Q3 | $670K | Buy |
48,070
+14,065
| +41% | +$201K | ﹤0.01% | 3545 |
|
|
2024
Q2 | $469K | Sell |
34,005
-137,045
| -80% | -$2.01M | ﹤0.01% | 3431 |
|
|
2024
Q1 | $2.83M | Buy |
171,050
+71,125
| +71% | +$1.06M | ﹤0.01% | 2141 |
|
|
2023
Q4 | $1.46M | Sell |
99,925
-740
| -0.7% | -$8.97K | ﹤0.01% | 2514 |
|
|
2023
Q3 | $1.24M | Buy |
100,665
+4,234
| +4% | +$55.2K | ﹤0.01% | 2340 |
|
|
2023
Q2 | $1.15M | Sell |
96,431
-56,567
| -37% | -$739K | ﹤0.01% | 2731 |
|
|
2023
Q1 | $2.05M | Buy |
152,998
+62,985
| +70% | +$1.23M | ﹤0.01% | 2007 |
|
|
2022
Q4 | $1.94M | Sell |
90,013
-41,733
| -32% | -$856K | ﹤0.01% | 2067 |
|
|
2022
Q3 | $2.64M | Buy |
131,746
+128,981
| +4,665% | +$2.74M | ﹤0.01% | 1948 |
|
|
2022
Q2 | $49K | Buy |
2,765
+562
| +26% | +$5.8K | ﹤0.01% | 4547 |
|
|
2022
Q1 | $22K | Sell |
2,203
-2,479
| -53% | -$32.8K | ﹤0.01% | 5095 |
|
|
2021
Q4 | $79K | Buy |
4,682
+3,403
| +266% | +$69.9K | ﹤0.01% | 4836 |
|
|
2021
Q3 | $30K | Buy |
+1,279
| New | +$30.7K | ﹤0.01% | 5025 |
|
Other funds holding DAWN
Citigroup's DAWN Position: Q2 2026 in Review
Citigroup sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 13,848 shares — an estimated $297K sold.
Citigroup first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $2.83M in Q1 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Citigroup reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 13,848 Day One Biopharmaceuticals shares in Q2 2026, an estimated $297K.
- Citigroup first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Citigroup's Day One Biopharmaceuticals position peaked at $2.83M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.